Newsfeeds Archive - Page 9 of 461

2 minute read

Eli Lilly Beefs Up Neuro Pipeline With Addition Of Preclinical ALS, Dementia Prospect

June 3, 2:05 PM

QurAlis has entered an exclusive license agreement with Eli Lilly for QRL-204, an antisense oligonucleotide for ALS and other neurodegenerative diseases. QurAlis will receive $45 million upfront, with potential milestones and royalties up to $577 million.

LLY

2 minute read

Why Is Arrowhead Pharmaceuticals Stock Trading Higher On Monday?

By Vandana Singh

June 3, 1:55 PM

Arrowhead Pharmaceuticals announced Phase 3 PALISADE study results showing significant triglyceride reduction in familial chylomicronemia syndrome patients treated with plozasiran.

ARWR

2 minute read

Why US Drug Giant Bristol Myers Squibb Stock Trading Up On Monday

By Vandana Singh

June 3, 12:51 PM

Bristol Myers Squibb's KRYSTAL-12 study reveals Krazati's significant benefits over chemotherapy for KRASG12C-mutated NSCLC, improving progression-free survival and response rates.

BMY

2 minute read

News

After Disappointing Bladder Cancer Data, Gilead Announces Encouraging Data From Gastric, Colorectal Cancer Studies

By Vandana Singh

June 3, 12:35 PM

Gilead Sciences and Arcus Biosciences report sustained efficacy and safety in the Phase 2 EDGE-Gastric study for upper GI cancers, showing improved progression-free survival and objective response rates. New data from the ARC-9 study highlights significant survival benefits in metastatic colorectal cancer.

GILD

2 minute read

Why Is Agios Pharmaceuticals Stock Trading Higher On Monday?

By Vandana Singh

June 3, 12:11 PM

Agios Pharmaceuticals shares rose after it announced its Phase 3 ENERGIZE-T study of mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia achieved the primary endpoint of transfusion reduction response.

AGIO

2 minute read

Johnson & Johnson At ASCO Highlights Long Term Data From Multiple Myeloma Drug, Shows Sustained Deep, Durable Responses In Pretreated Patients

By Vandana Singh

June 3, 12:01 PM

JNJ announced positive longer-term data from Phase 1/2 study of Tecvayli for RRMM. Results show deep and durable responses with a consistent safety profile.

JNJ

2 minute read

Obesity Data From Structure Therapeutics Shows Potential For Weight Loss Drug Candidate

By Vandana Singh

June 3, 11:11 AM

Structure Therapeutics announces Phase 2a results for GSBR-1290, showing significant weight loss in obesity study.

GPCR

2 minute read

Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients

By Vandana Singh

June 3, 10:27 AM

Moderna and Merck's Phase 2b study results for mRNA-4157 combined with Keytruda, showing improvements in recurrence-free and distant metastasis-free survival for high-risk melanoma patients. Phase 3 trials are now underway for melanoma and non-small cell lung cancer.

MRK

2 minute read

Zantac Heart Burn Continues For GSK As US Court Ruling Allows Thousands Of Zantac Lawsuits To Move Forward

By Vandana Singh

June 3, 9:53 AM

GSK shares fell as the Delaware State Court allowed over 70,000 lawsuits regarding the discontinued heartburn drug Zantac (ranitidine) to proceed. This ruling contradicts a Federal Court's 2022 decision dismissing similar cases, potentially increasing GSK's liability.

GSK

2 minute read

EXCLUSIVE: Canadian Mineral Exploration Firm Pasofino Gold Completes Drilling At ‘Bukon Jedeh’ Gold Project In Liberia

By Vandana Singh

June 3, 7:40 AM

Pasofino Gold completes its diamond core drilling program at Bukon Jedeh gold camp in Liberia, a priority target within the Dugbe Gold Project. Eleven holes drilled, sampling ongoing with results expected in July 2024. Encouraging visual results observed.

EFRGF